Aclaris Therapeutics (ACRS) CEO awarded 274,800 RSUs and 961,700 stock options

Rhea-AI Filing Summary

Aclaris Therapeutics CEO and director Walker Neal reported new equity awards granted on February 2, 2026. He received 274,800 restricted stock units, each representing the right to receive one share of common stock, and an employee stock option covering 961,700 shares of common stock.

The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on his continued service. The stock option, with a $3.61 exercise price per share, is exercisable as it vests over the same four-year schedule, also subject to continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Walker Neal

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	274,800	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	961,700	$0.00	--

Holdings After Transaction: Restricted Stock Units — 274,800 shares (Direct); Employee Stock Option (Right to Buy) — 961,700 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walker Neal

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/02/2026		A		274,800		(2)	(2)	Common Stock	274,800	$0	274,800	D
Employee Stock Option (Right to Buy)	$3.61	02/02/2026		A		961,700		(3)	02/01/2036	Common Stock	961,700	$0	961,700	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Aclaris Therapeutics (ACRS) CEO Walker Neal receive?

Walker Neal received 274,800 restricted stock units and an employee stock option for 961,700 shares. Each restricted stock unit represents one share of common stock, while the option allows him to buy shares at a fixed $3.61 exercise price.

When were the new equity awards to Aclaris (ACRS) CEO Walker Neal granted?

The equity awards were granted on February 2, 2026. On that date, Walker Neal received both 274,800 restricted stock units and an option over 961,700 shares, as disclosed in the Form 4 insider trading report.

How do Walker Neal’s restricted stock units at Aclaris (ACRS) vest?

The 274,800 restricted stock units vest in four equal annual installments. Vesting occurs on the first, second, third, and fourth anniversaries of February 2, 2026, and each installment requires Walker Neal to remain in continuous service under the company’s plan.

What are the vesting terms of Walker Neal’s stock option at Aclaris (ACRS)?

The 961,700-share stock option vests over four years, with 25% becoming exercisable on each of the first four anniversaries of February 2, 2026. Each vesting tranche is contingent on Walker Neal’s continuous service with Aclaris Therapeutics.

What is the exercise price of Walker Neal’s Aclaris (ACRS) stock option?

The employee stock option has a $3.61 exercise price per share. This means Walker Neal can purchase Aclaris common stock at $3.61 for each of the 961,700 shares covered, once the respective portions of the option have vested.

How many derivative securities does Walker Neal hold after these Aclaris (ACRS) grants?

Following these grants, Walker Neal beneficially owns 274,800 restricted stock units and 961,700 stock options. Both positions are reported as directly held, reflecting derivative interests tied to Aclaris Therapeutics common stock under the company’s compensation plan.